# Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

> **NCT00954122** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 35 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine XR (Seroquel XR)

## Key facts

- **NCT ID:** NCT00954122
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954122, "Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00954122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*